[{"orgOrder":0,"company":"Locust Walk","sponsor":"Innovation Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Dental and Oral Health","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Brilacidin","moa":"PDE4","graph1":"Dental and Oral Health","graph2":"Phase III","graph3":"Locust Walk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Oral","sponsorNew":"Locust Walk \/ Innovation Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Locust Walk \/ Innovation Pharmaceuticals"},{"orgOrder":0,"company":"ASEP Medical","sponsor":"Bohai Biomedical Technology Development Co.","pharmaFlowCategory":"D","therapeuticArea":"Dental and Oral Health","country":"","productType":"Peptide","year":"2022","type":"Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Dental and Oral Health","graph2":"Preclinical","graph3":"ASEP Medical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Solution","sponsorNew":"ASEP Medical \/ Bohai Biomedical Technology Development Co.","highestDevelopmentStatusID":"4","companyTruncated":"ASEP Medical \/ Bohai Biomedical Technology Development Co."},{"orgOrder":0,"company":"RxOMEG Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Pilocarpine Hydrochloride","moa":"","graph1":"Dental and Oral Health","graph2":"Preclinical","graph3":"RxOMEG Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Solution","sponsorNew":"RxOMEG Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"RxOMEG Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"ORAPHARMA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Minocycline Hydrochloride","moa":"","graph1":"Dental and Oral Health","graph2":"Approved","graph3":"ORAPHARMA","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Dry Powder","sponsorNew":"ORAPHARMA \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ORAPHARMA \/ Not Applicable"},{"orgOrder":0,"company":"ORAPHARMA","sponsor":"Bausch Health","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Minocycline Hydrochloride","moa":"","graph1":"Dental and Oral Health","graph2":"Approved","graph3":"ORAPHARMA","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Microspheres, Sustained Release","sponsorNew":"ORAPHARMA \/ Bausch Health","highestDevelopmentStatusID":"12","companyTruncated":"ORAPHARMA \/ Bausch Health"},{"orgOrder":0,"company":"Hyloris Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Tranexamic Acid","moa":"","graph1":"Dental and Oral Health","graph2":"Phase III","graph3":"Hyloris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Solution","sponsorNew":"Hyloris Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Hyloris Pharmaceuticals \/ Not Applicable"}]

Find Clinical Drug Pipelines for Dental and Oral Health

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Cosmoprof India
                          Not Confirmed
                          Cosmoprof India
                          Not Confirmed

                          Details : Tranexamic acid oral rinse is a USFDA approved antifibrinolytic agent, plasminogen inhibitor, which is being evaluatd in phase 3 clinical trials for the treatment of dental bleeding.

                          Brand Name : Tranexamic Acid Oral Rinse

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          February 14, 2024

                          Lead Product(s) : Tranexamic Acid

                          Therapeutic Area : Dental and Oral Health

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          Cosmoprof India
                          Not Confirmed
                          Cosmoprof India
                          Not Confirmed

                          Details : ARESTIN (minocycline HCl) Microspheres, 1mg is indicated as an adjunct to scaling and root planing (SRP) procedures for reduction of pocket depth in patients with adult periodontitis.

                          Brand Name : Arestin

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          May 18, 2023

                          Lead Product(s) : Minocycline Hydrochloride

                          Therapeutic Area : Dental and Oral Health

                          Highest Development Status : Approved

                          Sponsor : Bausch Health

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          Cosmoprof India
                          Not Confirmed
                          Cosmoprof India
                          Not Confirmed

                          Details : Pilocarpine is a muscarinic cholinergic agonist used on the eye to treat elevated intraocular pressure, various types of glaucoma, and to induce miosis. Also available orally to treat symptoms of dry mouth associated with Sjogren's syndrome and radiother...

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          February 01, 2023

                          Lead Product(s) : Pilocarpine Hydrochloride

                          Therapeutic Area : Dental and Oral Health

                          Highest Development Status : Preclinical

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          Cosmoprof India
                          Not Confirmed
                          Cosmoprof India
                          Not Confirmed

                          Details : The agreement permits Bohai Biomedical to conduct a feasibility study using Asep Inc.'s proprietary anti-bacterial peptide as an active ingredient. The peptide will be studied as an agent to mitigate and prevent erosive dental biofilm infections in an or...

                          Brand Name : Undisclosed

                          Molecule Type : Peptide

                          Upfront Cash : Undisclosed

                          October 17, 2022

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Dental and Oral Health

                          Highest Development Status : Preclinical

                          Sponsor : Bohai Biomedical Technology Development Co.

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          05

                          Locust Walk

                          Country arrow
                          Cosmoprof India
                          Not Confirmed

                          Locust Walk

                          Country arrow
                          Cosmoprof India
                          Not Confirmed

                          Details : This renewed engagement is a continuation of Innovation Pharmaceutical’s business relationship with Locust Walk toward realizing the market potential of the Company’s pipeline.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          January 29, 2020

                          Lead Product(s) : Brilacidin

                          Therapeutic Area : Dental and Oral Health

                          Highest Development Status : Phase III

                          Sponsor : Innovation Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank